Q3 EPS Estimates for Upstream Bio Raised by William Blair

Upstream Bio, Inc. (NASDAQ:UPB) – Analysts at William Blair increased their Q3 2025 earnings per share (EPS) estimates for Upstream Bio in a research note issued on Wednesday, November 5th. William Blair analyst M. Phipps now forecasts that the company will earn ($0.63) per share for the quarter, up from their prior estimate of ($0.78). The consensus estimate for Upstream Bio’s current full-year earnings is ($4.30) per share. William Blair also issued estimates for Upstream Bio’s Q4 2025 earnings at ($0.70) EPS, FY2025 earnings at ($2.58) EPS, Q1 2026 earnings at ($0.78) EPS, Q2 2026 earnings at ($0.68) EPS, Q3 2026 earnings at ($0.63) EPS, Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($2.37) EPS, FY2028 earnings at ($2.49) EPS and FY2029 earnings at ($2.66) EPS.

Other equities analysts have also issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, October 8th. Truist Financial initiated coverage on Upstream Bio in a research report on Tuesday, October 14th. They set a “buy” rating and a $47.00 price target for the company. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $47.00.

Upstream Bio Price Performance

NASDAQ UPB opened at $23.66 on Friday. Upstream Bio has a 1 year low of $5.14 and a 1 year high of $29.30. The company has a market capitalization of $1.28 billion and a PE ratio of -2.88. The company has a fifty day moving average of $19.94 and a 200 day moving average of $14.68.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.15. Upstream Bio had a negative net margin of 4,366.77% and a negative return on equity of 27.69%. The business had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.65 million.

Hedge Funds Weigh In On Upstream Bio

A number of large investors have recently bought and sold shares of the business. Bain Capital Life Sciences Investors LLC boosted its position in Upstream Bio by 6.3% during the second quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company’s stock worth $26,786,000 after purchasing an additional 144,216 shares in the last quarter. Norges Bank acquired a new position in shares of Upstream Bio during the 2nd quarter worth approximately $10,650,000. Geode Capital Management LLC raised its stake in shares of Upstream Bio by 57.5% during the 2nd quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock worth $7,101,000 after buying an additional 235,958 shares during the period. Woodline Partners LP lifted its position in shares of Upstream Bio by 5.8% during the 1st quarter. Woodline Partners LP now owns 557,063 shares of the company’s stock valued at $3,409,000 after buying an additional 30,552 shares in the last quarter. Finally, Parkman Healthcare Partners LLC acquired a new stake in Upstream Bio in the 1st quarter valued at $1,429,000.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.